About prelude therapeutics inc - PRLD
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
PRLD At a Glance
Prelude Therapeutics, Inc.
175 Innovation Boulevard
Wilmington, Delaware 19805
| Phone | 1-302-467-1280 | Revenue | 12.14M | |
| Industry | Biotechnology | Net Income | -99,498,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 73.429% | |
| Fiscal Year-end | 12 / 2026 | Employees | 79 | |
| View SEC Filings |
PRLD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 18.383 |
| Price to Book Ratio | 2.66 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.339 |
| Enterprise Value to Sales | 11.347 |
| Total Debt to Enterprise Value | 0.129 |
PRLD Efficiency
| Revenue/Employee | 153,670.886 |
| Income Per Employee | -1,259,468.354 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.077 |
PRLD Liquidity
| Current Ratio | 1.994 |
| Quick Ratio | 1.994 |
| Cash Ratio | 1.948 |
PRLD Profitability
| Gross Margin | 85.906 |
| Operating Margin | -861.334 |
| Pretax Margin | -819.588 |
| Net Margin | -819.588 |
| Return on Assets | -62.808 |
| Return on Equity | -99.45 |
| Return on Total Capital | -115.125 |
| Return on Invested Capital | -86.345 |
PRLD Capital Structure
| Total Debt to Total Equity | 25.918 |
| Total Debt to Total Capital | 20.583 |
| Total Debt to Total Assets | 12.588 |
| Long-Term Debt to Equity | 21.92 |
| Long-Term Debt to Total Capital | 17.408 |